What “third-party tested” proves, and what it doesn’t
Every peptide seller says third-party tested. Almost none of them say what was tested, which lot it came from, or who paid for it. The phrase points at a real legal requirement — a certificate of analysis has to accompany each bulk drug substance a compounder buys — and that requirement covers the powder the pharmacy ordered, not the vial that arrives at your door. In 2019 a certificate of analysis traveled with the material that put seven people in a clinic waiting room in trouble.
What this comes down to
- The statute requires bulk substances to meet a USP or National Formulary monograph where one exists, to be made by an FDA-registered establishment, and to be accompanied by valid certificates of analysis.
- A certificate of analysis describes a lot of raw material. It is not a test of the finished, reconstituted, shipped vial, and nothing requires it to be published.
- The FDA's own words after the 2019 glutathione cluster: quality should be built into production, and testing alone should not be relied on to ensure drug quality.
- On the FDA's compounding page, “peptide-related impurities” appears 19 times and “immunogenicity” 19 times across 31 substances. That is the recurring concern, not potency.
Where the phrase comes from
Section 503A of the Food, Drug, and Cosmetic Act sets three conditions on the bulk drug substances a compounding pharmacy may use. The substance has to comply with an applicable United States Pharmacopeia or National Formulary monograph if one exists, or else be a component of an approved drug, or else appear on the FDA's bulks list. It has to be manufactured by an establishment registered with the FDA. And it has to be accompanied by valid certificates of analysis, one for each bulk drug substance[1].
It is about the barrel of powder the pharmacy ordered. Not your vial, not your lot of finished product, not the sterility of what was drawn up on the day yours was made. A certificate of analysis is a supplier document, and the statute's requirement is that one exists and is valid — not that it is shown to you, and not that anyone independent repeated it.
The case where the certificate existed and failed anyway
The clearest illustration is the FDA's 2019 glutathione file. The material was repackaged by an FDA-registered repackager, and a certificate of analysis did accompany it — a translated copy of the foreign manufacturer's. The manufacturer's own invoice stated the ingredient was for dietary supplements only and not for pharmaceutical use. The certificate of analysis carried no such statement, and the powder went into injections[2]. The whole sequence is in its own article, including what the FDA's laboratory found when it tested the lots.
The line the agency wrote at the end of that investigation is the one worth keeping.
“It is critical that compounders understand that quality should be built into the drug production, and that testing alone should not be relied on to ensure drug quality.”
[2]
The four different tests people mean by one phrase
“Tested” collapses at least four separate questions, and a seller can truthfully claim one while failing another.
| The test | What it answers | What it does not |
|---|---|---|
| Identity | Is this molecule the one on the label | How much of it there is, or what else is in there |
| Purity or assay | What percentage is the intended peptide | Which impurities make up the remainder, or whether they matter |
| Sterility | Did anything grow from this sample | Whether endotoxin is present — that is a separate test |
| Bacterial endotoxin | Is endotoxin below a limit | Which limit, and whether it was calculated for your dose and route |
What each test answers, and what it leaves open.
The endotoxin row is not academic. In the 2019 cluster the limit had to be calculated from the maximum intravenous dose the patients received, and the samples came back as high as five times it. A pass against the wrong denominator is a pass.
Why peptides are harder than this sounds
Read the FDA's compounding page across all 31 substances and the same vocabulary keeps coming back. “Peptide-related impurities” appears 19 times. “Immunogenicity” appears 19 times. “API characterization” appears 8 times, “aggregation” 10, and for ipamorelin specifically the agency notes unnatural amino acids that add to the complexity of characterizing the peptide at all[3].
That is a quality complaint, not an efficacy one, and it is the agency's most consistent statement about this entire product category. A short synthetic peptide can carry deletion sequences, truncations, and stereochemical variants that a simple identity check will not separate. The analytical literature bears that out: the reference methods for identifying illegally traded peptides use liquid chromatography with tandem mass spectrometry and require a minimum of five identification points[4], and more polar peptides need a different separation chemistry again[5].
A certificate showing a single chromatographic peak at 99% is a weaker claim than it looks for a peptide. If a seller volunteers a document, the useful questions are which analytical method produced it, whether it covers the finished product or the raw powder, and what the lot number on it is.
The distinction that does most of the work
Two kinds of compounder exist and they are held to different standards. Drugs compounded in an FDA-registered outsourcing facility are subject to current good manufacturing practice requirements. Drugs compounded by a licensed pharmacist in a state-licensed pharmacy under section 503A are not[6]. Neither kind of product is FDA approved, and neither is reviewed for safety, effectiveness or quality before it is sold. But CGMP is the thing the FDA means by quality built into production, and only one of the two has it.
Which is why, on our reviews, the pharmacy question sits beside the price question. How we grade a seller covers what we look for; a company that will not name its pharmacy has answered.
How much of this market it covers
60 priced lines across 41 of the 190 sellers we have read first-hand are one of the peptides in this group — sermorelin, tesamorelin, BPC-157, ipamorelin, CJC-1295 or a thymosin product. Every one of them is a compounded preparation. The molecules differ enormously in what is known about them — tesamorelin has an approval and 26 trials, TB-500 has neither — but the manufacturing questions are identical across all of them, and they are the questions a buyer can actually get answered. The same goes for the compounded GLP-1s these sellers lead with, including the ones with a vitamin mixed in: what is claimed for the added B12 is a separate argument from how the vial was made, and both have to hold.
- Name the pharmacy. Then check whether it is a 503A or a registered outsourcing facility.
- Ask for the certificate of analysis with a lot number, and ask whether that lot is the one in your vial.
- Ask what the finished product was tested for, separately from the raw material — sterility and endotoxin are two tests, not one.
- Ask what the beyond-use date is based on.
- Ask what it costs in month two. Unrelated to quality, and still the question most people get wrong; our price method explains how we read a headline rate.
Questions people actually ask
What does a certificate of analysis actually certify?
It describes a specific lot of raw material against a set of specifications the supplier tested. Section 503A requires one to accompany each bulk drug substance a compounder uses. It is not a test of the finished vial you receive, and nothing requires it to be published or independently repeated.
Is third-party tested a regulated claim?
No. There is no definition it has to meet, no required scope, and no requirement to publish the document behind it. A seller can say it truthfully having tested identity on one lot of powder years ago.
Why does the FDA keep mentioning peptide-related impurities?
Because short synthetic peptides can carry deletion sequences, truncations and variants that a basic identity check does not separate, and because some of these peptides contain unnatural amino acids that make characterization harder. Across its compounding page the phrase appears 19 times.
Is a 503B outsourcing facility safer than a 503A pharmacy?
It is held to a higher manufacturing standard. Outsourcing facilities are subject to current good manufacturing practice requirements and 503A pharmacies are not. Neither produces an FDA-approved product, and neither is reviewed for safety, effectiveness or quality before marketing.
Sources
Every source here was fetched and read for this article, with the identifier taken off the record that came back and the claim it supports written down beside it. All of it was read in September 2026, the same session the rest of this page draws on.
- 1.21 U.S.C. 353a — Pharmacy compounding. Office of the Law Revision Counsel, United States Code, 2026. SourceSection 503A permits compounding with bulk drug substances that comply with an applicable USP or National Formulary monograph and the USP chapter on pharmacy compounding where one exists, or are components of approved drugs, or appear on the FDA's list; that are manufactured by an establishment registered under section 360; and that are accompanied by valid certificates of analysis for each bulk drug substance.
- 2.FDA highlights concerns with using dietary ingredient glutathione to compound sterile injectables. U.S. Food and Drug Administration, 2019. Source · Document dated June 2019A certificate of analysis accompanied the L-glutathione but was a translated copy of the manufacturer's and did not carry the manufacturer's statement that the ingredient was for dietary supplement use only; the FDA's closing guidance states that quality should be built into drug production and that testing alone should not be relied on to ensure drug quality; and endotoxin limits should be calculated using the maximum intravenous dose intended.
- 3.Substances in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration, 2026. Source · Document dated April 2026Across the 31 substances listed on the page, face-dated April 22, 2026, the phrase "peptide-related impurities" appears 19 times, "immunogenicity" 19 times, "API characterization" 8 times and "aggregation" 10 times; the ipamorelin acetate entry additionally notes unnatural amino acids that add to the complexity of peptide characterization.
- 4.Analysis of illegal peptide biopharmaceuticals frequently encountered by controlling agencies. Talanta, 2015. PMID 26003685 · doi:10.1016/j.talanta.2015.04.022An official medicines control laboratory screening method for counterfeit and illegal injectable peptide preparations uses liquid chromatography with tandem mass spectrometry, selectively detects 25 peptides, and incorporates the recommended minimum of five identification points.
- 5.Analysis of illegal peptide drugs via HILIC-DAD-MS. Talanta, 2017. PMID 28738623 · doi:10.1016/j.talanta.2017.06.034Lyophilized peptides under 5 kDa intended for subcutaneous injection are the ones most commonly traded online, and identifying the more polar ones requires hydrophilic interaction liquid chromatography rather than the reversed-phase methods used previously.
- 6.Compounding and the FDA: Questions and Answers. U.S. Food and Drug Administration, 2025. Source · Document dated September 2025Drugs compounded in outsourcing facilities are subject to current good manufacturing practice requirements while drugs compounded under section 503A are not, and compounded drugs of either kind are not FDA approved or reviewed for safety, effectiveness or quality before marketing.
Key figures